| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 30.37 | 44.0% | |
| Total Income | 31.70 | 46.6% | 77219.8% |
| Expenditure | 30.64 | 44.3% | 3121.7% |
| PBT | 1.06 | 75.6% | 216.8% |
| Net Profit | 1.06 | 75.6% | 216.8% |
| OPM | -0.87% | 0.65pp | |
| NPM | 3.35% | 3.99pp | |
| EPS | 0.07 | 75.9% | 16.7% |
Core operations ran at a slight loss (OPM -0.9%) and the entire ₹1.06cr profit came from other income rather than the core healthcare-data business, while the prior-year base (near-zero revenue) makes the reported turnaround largely a base-effect artifact.
TAKE Ltd Reports Q1 FY27 Profit of ₹1.06 Cr, Revenue ₹30.37 Cr
11 Aug 2026 · 11 Aug, 6:56 pm
Summary
TAKE Limited announced strong Q1 FY27 results with consolidated revenue reaching ₹30.37 Crore and consolidated net profit turning positive at ₹1.06 Crore, a significant improvement from a net loss in the previous year. Finance costs saw a dramatic reduction of 99.62% year-over-year. The company also reported a robust standalone performance with substantial revenue growth and a turnaround to profitability. Management highlighted the successful stabilization of operations and the strategic entry into the burgeoning Longevity and Anti-Ageing sector, positioning TAKE Limited at the intersection of life sciences, technology, and consumer wellness for future growth.
Key Highlights
- 1
TAKE Limited reported a consolidated revenue of ¥3,037.33 Lakhs (₹30.37 Crore) for Q1 FY27, a significant increase from nil revenue in the prior-year period.
- 2
Consolidated Net Profit after tax stood at ₹1.06 Crore, marking a strong return to profitability from a net loss of ₹(91.00) Lakhs in Q1 FY26.
- 3
Finance costs dramatically decreased by 99.62% year-over-year, reaching ₹0.07 Lakhs, reflecting improved financial health.
- 4
Basic and Diluted Earnings Per Share turned positive at ₹0.07 per share, a substantial improvement from ₹(0.06) per share in the same period last year.
- 5
Standalone Revenue from Operations surged to ₹1,196.90 Lakhs from ₹0.65 Lakhs in Q1 FY26, with standalone Net Profit also turning profitable.
- 6
The company announced a strategic entry into the Longevity, Biohacking, and Preventive Healthcare market, aiming to leverage a dual business model focused on nutraceuticals and digital longevity solutions.
Management Comments
Parmeshvar Dhangare
Our Q1 FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finance costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness. By combining our regulatory and clinical domain expertise with cutting-edge biohacking and predictive digital tools, we are building a scalable, high-margin platform that addresses the multi-billion-dollar shift toward proactive health optimization.
Informational and educational content only. Not investment advice.